Jin Lei, founder of Genesci Pharmaceutical, stated at a J.P. Morgan summit that AI will revolutionize traditional pharmaceutical development. Genesci has leveraged AI to design innovative enzymes that overcome drug resistance, with one product for bacterial vaginosis entering Phase I clinical trials. The company has seen a 50% reduction in early research cycles and a 33% decrease in process optimization costs due to AI integration. AI
影响 AI integration is accelerating drug discovery and reducing costs, potentially leading to faster development of new treatments.
排序理由 The cluster discusses a founder's opinion on AI's impact on pharmaceuticals and mentions a product in early clinical trials, fitting commentary on industry trends.
AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →